Your browser doesn't support javascript.
loading
Nanoalum adjuvanted vaccines: small details make a big difference.
Raponi, Arianna; Brewer, James M; Garside, Paul; Laera, Donatello.
Afiliación
  • Raponi A; Institute of Infection, Immunity and Inflammation, 120 Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, G12 8TA, Scotland, United Kingdom. Electronic address: a.raponi.1@research.gla.ac.uk.
  • Brewer JM; Institute of Infection, Immunity and Inflammation, 120 Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, G12 8TA, Scotland, United Kingdom.
  • Garside P; Institute of Infection, Immunity and Inflammation, 120 Glasgow Biomedical Research Centre, University of Glasgow, Glasgow, G12 8TA, Scotland, United Kingdom.
  • Laera D; GlaxoSmithKline Biologicals SA, Technical and Research Development- Drug Product, Siena, Italy.
Semin Immunol ; 56: 101544, 2021 08.
Article en En | MEDLINE | ID: mdl-34895823
Purified vaccine antigens offer important safety and reactogenicity advantages compared with live attenuated or whole killed virus and bacterial vaccines. However, they require the addition of adjuvants to induce the magnitude, duration and quality of immune response required to achieve protective immunity. Aluminium salts have been used as adjuvants in vaccines for almost a century. In the literature, they are often referred to as aluminium-based adjuvants (ABAs), or aluminium salt-containing adjuvants or more simply "alum". All these terms are used to group aluminium suspensions that are very different in terms of atomic composition, size, and shape. They differ also in stability, antigen-adsorption, and antigen-release kinetics. Critically, these parameters also have a profound effect on the character and magnitude of the immune response elicited. Recent findings suggest that, by reducing the size of aluminium from micro to nanometers, a more effective adjuvant is obtained, together with the ability to sterile filter the vaccine product. However, the behaviour of aluminium nanoparticles in vaccine formulations is different from microparticles, requiring specific formulation strategies, as well as a more detailed understanding of how formulation influences the immune response generated. Here we review the current state of art of aluminium nanoparticles as adjuvants, with a focus on their immunobiology, preparation methods, formulation optimisation and stabilisation.
Asunto(s)
Palabras clave

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas / Nanopartículas Límite: Humans Idioma: En Revista: Semin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Vacunas / Nanopartículas Límite: Humans Idioma: En Revista: Semin Immunol Asunto de la revista: ALERGIA E IMUNOLOGIA Año: 2021 Tipo del documento: Article